Skip to main content
. 2017 May 23;12(8):1291–1300. doi: 10.2215/CJN.05300516

Figure 5.

Figure 5.

Long-term eplerenone administration on oxidative stress and urinary renal injury biomarkers. (A) 8-Hydroxylated guanosine (white bars) in placebo 24 (squared bars), eplerenone 0 (gray bars), and eplerenone 24 (black bars). (B) Percentage of change in urinary HSP72 compared with baseline in placebo (white bars) and eplerenone 24 (black bars). (C) Urinary KIM-1 in placebo- (○) or eplerenone-treated pediatric patients (■). (D) TGF-β1 at baseline and 12 months of treatment. The data are expressed as mean±SD. Cr, creatinine; Ep0, eplerenone month 0; Ep24, eplerenone month 24; P0, placebo month 0; P24, placebo month 24.